Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ryosei Sasaki"'
Autor:
Yoshiaki Okano, Norifumi Sugawara, Tadashi Shimoyama, Yasuhiko Tsukushi, Akihiro Otsu, Takeshi Sugawara, Kazuki Kiyohara, Shugo Kowata, Ryosei Sasaki, Ichiro Hanamura, Wataru Izumita, Yuka Takemasa-Fujisawa, Shigeki Ito, Takahiro Mine, Yuzo Suzuki, Tatsuo Oyake, Maki Nishiya, Shinri Miyajima
Publikováno v:
Blood. 134:4865-4865
BACKGROUND: Febrile neutropenia (FN) is often observed in patients with hematological malignancies (HEM), especially in those with acute leukemia (AL). Monotherapy with antipseudomonal beta-lactams, such as cefepime, carbapenem, or piperacillin-tazob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e89d956508c014f536f4be81c8ef3fb
https://doi.org/10.1182/blood-2019-131305
https://doi.org/10.1182/blood-2019-131305
Autor:
Maki Asahi, Suzuki Yuzo, Ryosei Sasaki, Sugawara Norifumi, Yasuhiko Tsukushi, Fujishima Yukiteru, Yoji Ishida, Shigeki Ito, Shugo Kowata, Tatsuo Oyake, Kazunori Murai, Tadashi Shimoyama
Publikováno v:
Blood. 120:2186-2186
Abstract 2186 Background: Ponatinib (AP24534) is identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML (Chronic Myeloid Le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b5173117ec336da9b2e63c21ba4001c
https://doi.org/10.1182/blood.v120.21.2186.2186
https://doi.org/10.1182/blood.v120.21.2186.2186